Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Impact of COVID-19 on the Delivery of Systemic Anti-Cancer Treatment at Guy's Cancer Centre.
Russell B, Moss C, Tsotra E, Gousis C, Josephs D, Enting D, Karampera C, Khan M, Roca J, Sita-Lumsden A, Owczarczyk K, Wylie H, Haire A, Smith D, Zaki K, Swampillai A, Lei M, Manik V, Michalarea V, Kristeleit R, Mera A, Sawyer E, Flanders L, De Francesco I, Papa S, Ross P, Spicer J, Dann B, Jogia V, Shaunak N, Kristeleit H, Rigg A, Montes A, Van Hemelrijck M, Dolly S. Russell B, et al. Among authors: michalarea v. Cancers (Basel). 2022 Jan 6;14(2):266. doi: 10.3390/cancers14020266. Cancers (Basel). 2022. PMID: 35053432 Free PMC article.
EGFR-mutated lung cancer in Li-Fraumeni syndrome.
Michalarea V, Calcasola M, Cane P, Tobal K, Izatt L, Spicer J. Michalarea V, et al. Lung Cancer. 2014 Sep;85(3):485-7. doi: 10.1016/j.lungcan.2014.06.017. Epub 2014 Jun 30. Lung Cancer. 2014. PMID: 25047674
Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry.
Mostaghim A, Minkove S, Aguilar-Company J, Ruiz-Camps I, Eremiev-Eremiev S, Dettorre GM, Fox L, Tondini C, Brunet J, Carmona-García M, Lambertini M, Bower M, Newsom-Davis T, Sharkey R, Pria AD, Rossi M, Plaja A, Salazar R, Sureda A, Prat A, Michalarea V, Van Hemelrijck M, Sita-Lumsden A, Bertuzzi A, Rimassa L, Rossi S, Rizzo G, Pedrazzoli P, Lee AJ, Murphy C, Belessiotis K, Diamantis N, Mukherjee U, Pommeret F, Stoclin A, Martinez-Vila C, Bruna R, Gaidano G, D'Avanzo F, Gennari A, Athale J, Eichacker P, Pinato DJ, Torabi-Parizi P, Cortellini A; OnCovid study group. Mostaghim A, et al. Among authors: michalarea v. Int J Infect Dis. 2024 Feb;139:13-20. doi: 10.1016/j.ijid.2023.11.021. Epub 2023 Nov 27. Int J Infect Dis. 2024. PMID: 38029831 Free article.
Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.
George A, Kristeleit R, Rafii S, Michie CO, Bowen R, Michalarea V, van Hagen T, Wong M, Rallis G, Molife LR, Lopez J, Banerji U, Banerjee SN, Gore ME, de Bono JS, Kaye SB, Yap TA. George A, et al. Among authors: michalarea v. Eur J Cancer. 2017 May;76:52-59. doi: 10.1016/j.ejca.2017.01.020. Epub 2017 Mar 6. Eur J Cancer. 2017. PMID: 28273485 Free article.
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma.
Au L, Hatipoglu E, Robert de Massy M, Litchfield K, Beattie G, Rowan A, Schnidrig D, Thompson R, Byrne F, Horswell S, Fotiadis N, Hazell S, Nicol D, Shepherd STC, Fendler A, Mason R, Del Rosario L, Edmonds K, Lingard K, Sarker S, Mangwende M, Carlyle E, Attig J, Joshi K, Uddin I, Becker PD, Sunderland MW, Akarca A, Puccio I, Yang WW, Lund T, Dhillon K, Vasquez MD, Ghorani E, Xu H, Spencer C, López JI, Green A, Mahadeva U, Borg E, Mitchison M, Moore DA, Proctor I, Falzon M, Pickering L, Furness AJS, Reading JL, Salgado R, Marafioti T, Jamal-Hanjani M; PEACE Consortium; Kassiotis G, Chain B, Larkin J, Swanton C, Quezada SA, Turajlic S; TRACERx Renal Consortium. Au L, et al. Cancer Cell. 2021 Nov 8;39(11):1497-1518.e11. doi: 10.1016/j.ccell.2021.10.001. Epub 2021 Oct 28. Cancer Cell. 2021. PMID: 34715028 Free PMC article.
Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay.
Orlando F, Romanel A, Trujillo B, Sigouros M, Wetterskog D, Quaini O, Leone G, Xiang JZ, Wingate A, Tagawa S, Jayaram A, Linch M; PEACE Consortium; Jamal-Hanjani M, Swanton C, Rubin MA, Wyatt AW, Beltran H, Attard G, Demichelis F. Orlando F, et al. NAR Cancer. 2022 May 27;4(2):zcac016. doi: 10.1093/narcan/zcac016. eCollection 2022 Jun. NAR Cancer. 2022. PMID: 35664542 Free PMC article.
Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue.
Litchfield K, Stanislaw S, Spain L, Gallegos LL, Rowan A, Schnidrig D, Rosenbaum H, Harle A, Au L, Hill SM, Tippu Z, Thomas J, Thompson L, Xu H, Horswell S, Barhoumi A, Jones C, Leith KF, Burgess DL, Watkins TBK, Lim E, Birkbak NJ, Lamy P, Nordentoft I, Dyrskjøt L, Pickering L, Hazell S, Jamal-Hanjani M; PEACE Consortium; Larkin J, Swanton C, Alexander NR, Turajlic S. Litchfield K, et al. Cell Rep. 2020 May 5;31(5):107550. doi: 10.1016/j.celrep.2020.107550. Cell Rep. 2020. PMID: 32375028 Free article.
Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit.
Papadatos-Pastos D, Roda D, De Miguel Luken MJ, Petruckevitch A, Jalil A, Capelan M, Michalarea V, Lima J, Diamantis N, Bhosle J, Molife LR, Banerji U, de Bono JS, Popat S, O'Brien MER, Yap TA. Papadatos-Pastos D, et al. Among authors: michalarea v. Eur J Cancer. 2017 Apr;75:56-62. doi: 10.1016/j.ejca.2016.12.026. Epub 2017 Feb 17. Eur J Cancer. 2017. PMID: 28214659
Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience.
Coleman N, Michalarea V, Alken S, Rihawi K, Lopez RP, Tunariu N, Petruckevitch A, Molife LR, Banerji U, De Bono JS, Welsh L, Saran F, Lopez J. Coleman N, et al. Among authors: michalarea v. J Neurooncol. 2018 Aug;139(1):107-116. doi: 10.1007/s11060-018-2847-z. Epub 2018 Apr 10. J Neurooncol. 2018. PMID: 29637509 Clinical Trial.
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours.
de Bono J, Lin CC, Chen LT, Corral J, Michalarea V, Rihawi K, Ong M, Lee JH, Hsu CH, Yang JC, Shiah HS, Yen CJ, Anthoney A, Jove M, Buschke S, Fuertig R, Schmid U, Goeldner RG, Strelkowa N, Huang DC, Bogenrieder T, Twelves C, Cheng AL. de Bono J, et al. Among authors: michalarea v. Br J Cancer. 2020 Apr;122(9):1324-1332. doi: 10.1038/s41416-020-0774-1. Epub 2020 Mar 12. Br J Cancer. 2020. PMID: 32161368 Free PMC article. Clinical Trial.
21 results